Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
C1 esterase inhibitor (human)
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
B06AC02
|
| gptkbp:form |
lyophilized powder for solution for injection
|
| gptkbp:indication |
prevention of hereditary angioedema attacks
|
| gptkbp:manufacturer |
gptkb:CSL_Behring
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
dizziness
headache injection site reaction hypersensitivity |
| gptkbp:storage |
refrigerated
|
| gptkbp:usedFor |
gptkb:hereditary_hemorrhagic_telangiectasia
|
| gptkbp:bfsParent |
gptkb:C1_esterase_inhibitor
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Haegarda
|